pan-PI3K inhibitor · small molecule

buparlisib

0 active trials across 3 of our biomarkers, targeting PI3K. Not approved for any biomarker on marked.bio yet.

Also known as BKM120, AN2025.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

Biomarker	All trials	Furthest active phase
BRAF V600E	3	–
EGFR exon 19 deletion / L858R	1	–
PIK3CA activating mutation	4	–

Trials

0 of 8 trials shown

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

Unknown status Phase 2 University Hospital Tuebingen Started 2015 NCT02452294

buparlisib

Patients BRAF V600 mutation positive:

BRAF V600EMalignant Melanoma, Metastases
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Completed Phase 2 SCRI Development Innovations Started 2014 NCT01487265

buparlisiberlotinib FDA EU

Exon 19 deletion

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Completed Phase 2 Pfizer Started 2014 NCT02159066

encorafenib FDA EUbinimetinib FDA EUribociclibinfigratinibbuparlisibcapmatinib

Documented evidence of BRAF V600 mutation.

BRAF V600EMelanoma
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Completed Phase 2 Novartis Started 2014 NCT01923168

alpelisib FDA EUbuparlisib

Patient has diagnostic biopsy available for the analysis of PIK3CA mutation and Ki67 level.

PIK3CA activating mutationBreast Cancer
BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers

Withdrawn Phase 2 University of Utah Started 2014 NCT01550380

buparlisib

Tumor must demonstrate PI3 Kinase pathway activation: defined as PIK3CA gene mutation, PTEN gene mutation, or PTEN null/low protein expression.

PIK3CA activating mutationEndometrial Cancer
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Completed Phase 1/2 University of California, San Francisco Started 2012 NCT01512251

buparlisibvemurafenib FDA EU

BRAFV600E or BRAFV600K mutation-positive

BRAF V600EBRAF Mutant Metastatic Melanoma
BKM120 in Cancers With PIK3CA Activating Mutations

Withdrawn Phase 2 Massachusetts General Hospital Started 2012 NCT01501604

buparlisib

Cancer must have at least one of the following PIK3CA mutations: E542K, E545K, H1047R, H1047L.

PIK3CA activating mutationLung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Completed Phase 2 L. Nicolas Gonzalez Castro, MD, PhD Started 2011 NCT01339052

buparlisib

…ior surgery must demonstrate activation of the PI3K pathway through one of the following: PIK3CA mutation of PIK3R1 mutation, PTEN negativity (\<10% of tumor cells staining) oh immunohistochemist…

PIK3CA activating mutationGlioblastoma